Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Estess, JM; Moliterno, DJ
   Thrombolytic therapy for acute myocardial infarction
   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
   
   J.M. Estess e D.J. Moliterno, "Thrombolytic therapy for acute myocardial infarction", CATHET C IN, 53(4), 2001, pp. 489-498
2. Antman, EM; de Lemos, JA; Braunwald, E
   Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction
   EUROPEAN HEART JOURNAL SUPPLEMENTS
   
   E.M. Antman et al., "Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction", EUR H J SUP, 3(A), 2001, pp. A8-A13
3. Dey, S; Chitte, RR
   A new thrombolytic enzyme for acute myocardial infarction
   MEDICINAL CHEMISTRY RESEARCH
   
   S. Dey e R.R. Chitte, "A new thrombolytic enzyme for acute myocardial infarction", MED CHEM RE, 10(7-8), 2001, pp. 507-515
4. Sobel, BE
   Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications
   CORONARY ARTERY DISEASE
   
   B.E. Sobel, "Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications", CORON ART D, 12(4), 2001, pp. 323-332
5. Chern, I; Sharma, A; Dennis, D
   Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction
   JOURNAL OF THROMBOSIS AND THROMBOLYSIS
   
   I. Chern et al., "Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction", J THROMB TH, 12(2), 2001, pp. 185-191
6. Aoki, S; Shimizu, N; Shimonishi, M; Kitagawa, M; Okumura, K; Tanigawara, Y
   Influence of sugar chain on fibrin affinity of recombinant t-PA
   BIOLOGICAL & PHARMACEUTICAL BULLETIN
   
   S. Aoki et al., "Influence of sugar chain on fibrin affinity of recombinant t-PA", BIOL PHAR B, 24(3), 2001, pp. 295-298
7. Scrutinio, D; Cimminiello, C; Marubini, E; Pitzalis, MV; Di Biase, M; Rizzon, P
   Ticlopidine versus aspirin after myocardial infarction (STAMI) trial
   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
   
   D. Scrutinio et al., "Ticlopidine versus aspirin after myocardial infarction (STAMI) trial", J AM COL C, 37(5), 2001, pp. 1259-1265
8. Aoki, S; Kitagawa, M; Okumura, K
   Pharmacokinetic studies of Gln117 tissue-type plasminogen activator in rats
   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
   
   S. Aoki et al., "Pharmacokinetic studies of Gln117 tissue-type plasminogen activator in rats", J PHARM B, 26(3), 2001, pp. 453-462
9. Voipio, V; Kuisma, M; Alaspaa, A; Manttari, M; Rosenberg, P
   Thrombolytic treatment of acute myocardial infarction after out-of-hospital cardiac arrest
   RESUSCITATION
   
   V. Voipio et al., "Thrombolytic treatment of acute myocardial infarction after out-of-hospital cardiac arrest", RESUSCITAT, 49(3), 2001, pp. 251-258
10. Coussement, PK; Bassand, JP; Convens, C; Vrolix, M; Boland, J; Grollier, G; Michels, R; Vahanian, A; Vanderheyden, M; Rupprecht, HJ; Van de Werf, F
    A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction - The PENTALYSE study
    EUROPEAN HEART JOURNAL
    
    P.K. Coussement et al., "A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction - The PENTALYSE study", EUR HEART J, 22(18), 2001, pp. 1716-1724
11. Llevadot, J; Giugliano, RP; Antman, EM
    Bolus fibrinolytic therapy in acute myocardial infarction
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    
    J. Llevadot et al., "Bolus fibrinolytic therapy in acute myocardial infarction", J AM MED A, 286(4), 2001, pp. 442-449
12. Eikelboom, JW; Mehta, SR; Pogue, J; Yusuf, S
    Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials -Intracranial hemorrhage in trials of bolus thrombolytic therapy
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    
    J.W. Eikelboom et al., "Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials -Intracranial hemorrhage in trials of bolus thrombolytic therapy", J AM MED A, 285(4), 2001, pp. 444-450
13. Shieh, SJ; Chiu, HY; Shi, GY; Wu, CM; Wang, JC; Chen, CH; Wu, HL
    A novel platelet-rich arterial thrombosis model in rabbits - Simple, reproducible, and dynamic real-time easurement by using double-opposing inverted-sutures model
    THROMBOSIS RESEARCH
    
    S.J. Shieh et al., "A novel platelet-rich arterial thrombosis model in rabbits - Simple, reproducible, and dynamic real-time easurement by using double-opposing inverted-sutures model", THROMB RES, 103(5), 2001, pp. 363-376
14. Sinnaeve, P; Van de Werf, F
    Thrombolytic therapy - State of the art
    THROMBOSIS RESEARCH
    
    P. Sinnaeve e F. Van de Werf, "Thrombolytic therapy - State of the art", THROMB RES, 103, 2001, pp. S71-S79
15. Rebello, SS; Kasiewski, CJ; Bentley, RG; Morgan, SR; Chu, V; Bostwick, JS; Klein, SI; Perrone, MH; Leadley, RJ
    Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs
    THROMBOSIS RESEARCH
    
    S.S. Rebello et al., "Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs", THROMB RES, 102(3), 2001, pp. 261-271
16. Armstrong, PW; Collen, D
    Fibrinolysis for acute myocardial infarction - Current status and new horizons for pharmacological reperfusion, Part 1
    CIRCULATION
    
    P.W. Armstrong e D. Collen, "Fibrinolysis for acute myocardial infarction - Current status and new horizons for pharmacological reperfusion, Part 1", CIRCULATION, 103(23), 2001, pp. 2862-2866
17. Callahan, KP; Malinin, AI; Gurbel, PA; Alexander, JH; Granger, CB; Serebruany, VL
    Platelet function and fibrinolytic agents: Two sides of a coin?
    CARDIOLOGY
    
    K.P. Callahan et al., "Platelet function and fibrinolytic agents: Two sides of a coin?", CARDIOLOGY, 95(2), 2001, pp. 55-60
18. Rebello, SS; Bentley, RG; Morgan, SR; Kasiewski, CJ; Chu, V; Perrone, MH; Leadley, RJ
    Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis
    BRITISH JOURNAL OF PHARMACOLOGY
    
    S.S. Rebello et al., "Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis", BR J PHARM, 133(7), 2001, pp. 1190-1198
19. Giugliano, RP; McCabe, CH; Antman, EM; Cannon, CP; Van de Werf, F; Wilcox, RG; Braunwald, E
    Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
    AMERICAN HEART JOURNAL
    
    R.P. Giugliano et al., "Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage", AM HEART J, 141(5), 2001, pp. 742-750
20. Collen, D; Lijnen, HR
    Recent developments in thrombolytic therapy
    FIBRINOLYSIS & PROTEOLYSIS
    
    D. Collen e H.R. Lijnen, "Recent developments in thrombolytic therapy", FIBRINOL PR, 14(2-3), 2000, pp. 66-72
21. Priglinger, U; Huber, K
    Thrombolytic therapy in acute myocardial infarction
    DRUGS & AGING
    
    U. Priglinger e K. Huber, "Thrombolytic therapy in acute myocardial infarction", DRUG AGING, 16(4), 2000, pp. 301-312
22. Iqbal, O; Messmore, H; Hoppensteadt, D; Fareed, J; Wehrmacher, T
    State-of-the-art review - Thrombolytic drugs in acute myocardial infarction
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    
    O. Iqbal et al., "State-of-the-art review - Thrombolytic drugs in acute myocardial infarction", CL APPL T-H, 6(1), 2000, pp. 1-13
23. Sauaia, A; Ralston, D; Schluter, WW; Marciniak, TA; Havranek, EP; Dunn, TR
    Influencing care in acute myocardial infarction: A randomized trial comparing 2 types of intervention
    AMERICAN JOURNAL OF MEDICAL QUALITY
    
    A. Sauaia et al., "Influencing care in acute myocardial infarction: A randomized trial comparing 2 types of intervention", AM J MED QU, 15(5), 2000, pp. 197-206
24. Davidian, MM; Powell, A; Benenati, JF; Katzen, BT; Becker, GJ; Zemel, G
    Initial results of reteplase in the treatment of acute lower extremity arterial occlusions
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
    
    M.M. Davidian et al., "Initial results of reteplase in the treatment of acute lower extremity arterial occlusions", J VAS INT R, 11(3), 2000, pp. 289-294
25. Laird, JR
    Pharmacologic therapies in the treatment of peripheral vascular disease: Clinical experience with reteplase, a third-generation thrombolytic
    JOURNAL OF INVASIVE CARDIOLOGY
    
    J.R. Laird, "Pharmacologic therapies in the treatment of peripheral vascular disease: Clinical experience with reteplase, a third-generation thrombolytic", J INVAS CAR, 12, 2000, pp. 27B-32B
26. Gurewich, V
    Fibrinolysis: an unfinished agenda
    BLOOD COAGULATION & FIBRINOLYSIS
    
    V. Gurewich, "Fibrinolysis: an unfinished agenda", BL COAG FIB, 11(5), 2000, pp. 401-408
27. Binbrek, A; Rao, N; Absher, PM; Van de Werf, F; Sobel, BE
    The relative rapidity of recanalization induced by recombinant tissue-typeplasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods
    CORONARY ARTERY DISEASE
    
    A. Binbrek et al., "The relative rapidity of recanalization induced by recombinant tissue-typeplasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods", CORON ART D, 11(5), 2000, pp. 429-435
28. Sabatine, MS; Tu, TM; Jang, IK
    Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    
    M.S. Sabatine et al., "Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase", J THROMB TH, 10(2), 2000, pp. 189-196
29. Aoki, S; Shimizu, N; Koyama, J; Kato, Y; Kitagawa, M; Okumura, K; Tanigawara, Y
    Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    S. Aoki et al., "Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA", BIOL PHAR B, 23(4), 2000, pp. 477-481
30. Antman, EM; Gibson, CM; de Lemos, JA; Giugliano, RP; McCabe, CH; Coussement, P; Menown, I; Nienaber, CA; Rehders, TC; Frey, NJ; Van der Wieken, R; Andresen, D; Scherer, J; Anderson, K; Van de Werf, F; Braunwald, E
    Combination reperfusion therapy with abciximab and reduced dose reteplase:results from TIMI 14
    EUROPEAN HEART JOURNAL
    
    E.M. Antman et al., "Combination reperfusion therapy with abciximab and reduced dose reteplase:results from TIMI 14", EUR HEART J, 21(23), 2000, pp. 1944-1953
31. Mehta, SR; Eikelboom, JW; Yusuf, S
    Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis
    LANCET
    
    S.R. Mehta et al., "Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis", LANCET, 356(9228), 2000, pp. 449-454
32. Harder, S; Klinkhardt, U
    Thrombolytics - Drug interactions of clinical significance
    DRUG SAFETY
    
    S. Harder e U. Klinkhardt, "Thrombolytics - Drug interactions of clinical significance", DRUG SAFETY, 23(5), 2000, pp. 391-399
33. Rebello, SS; Blank, HS; Lucchesi, BR
    Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis
    THROMBOSIS RESEARCH
    
    S.S. Rebello et al., "Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis", THROMB RES, 98(6), 2000, pp. 531-540
34. Huber, K
    Increase of efficacy of thrombolytic therapy in acute myocardial infarction by improvement of the characteristics of new fibrinolytic agents
    WIENER KLINISCHE WOCHENSCHRIFT
    
    K. Huber, "Increase of efficacy of thrombolytic therapy in acute myocardial infarction by improvement of the characteristics of new fibrinolytic agents", WIEN KLIN W, 112(17), 2000, pp. 742-748
35. Brass, LM; Lichtman, JH; Wang, Y; Gurwitz, JH; Radford, MJ; Krumholz, HM
    Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction - Results from the cooperative cardiovascular project
    STROKE
    
    L.M. Brass et al., "Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction - Results from the cooperative cardiovascular project", STROKE, 31(8), 2000, pp. 1802-1811
36. Yoshida, Y; Hirai, M; Yamada, T; Tsuji, Y; Kondo, T; Inden, Y; Akahoshi, M; Murakami, Y; Tsuda, M; Tsuboi, N; Hirayama, H; Okamoto, M; Ito, T; Saito, H; Toyama, J
    Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias - Evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias
    CIRCULATION
    
    Y. Yoshida et al., "Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias - Evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias", CIRCULATION, 101(6), 2000, pp. 624-630
37. Pratico, D; Cyrus, T; Li, HW; FitzGerald, GA
    Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis
    BLOOD
    
    D. Pratico et al., "Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis", BLOOD, 96(12), 2000, pp. 3823-3826
38. McRedmond, JP; Harriott, P; Walker, B; Fitzgerald, DJ
    Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1
    BLOOD
    
    J.P. McRedmond et al., "Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1", BLOOD, 95(4), 2000, pp. 1301-1308
39. Verstraete, M
    Third-generation thrombolytic drugs
    AMERICAN JOURNAL OF MEDICINE
    
    M. Verstraete, "Third-generation thrombolytic drugs", AM J MED, 109(1), 2000, pp. 52-58
40. DeGeare, VS; Stone, GW; Grines, L; Brodie, BR; Cox, DA; Garcia, E; Wharton, TP; Boura, JA; O'Neill, WW; Grines, CL
    Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials)
    AMERICAN JOURNAL OF CARDIOLOGY
    
    V.S. DeGeare et al., "Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials)", AM J CARD, 86(1), 2000, pp. 30-34
41. Fleming, TR
    Design and interpretation of equivalence trials
    AMERICAN HEART JOURNAL
    
    T.R. Fleming, "Design and interpretation of equivalence trials", AM HEART J, 139(4), 2000, pp. S171-S176
42. Califf, RM
    Combination therapy for acute myocardial infarction: Fibrinolytic therapy and glycoprotein IIb/IIIa inhibition
    AMERICAN HEART JOURNAL
    
    R.M. Califf, "Combination therapy for acute myocardial infarction: Fibrinolytic therapy and glycoprotein IIb/IIIa inhibition", AM HEART J, 139(2), 2000, pp. S33-S37
43. Baron, EM; Burke, JA; Akhtar, N; Young, WF
    Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    
    E.M. Baron et al., "Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction", CATHET C IN, 48(4), 1999, pp. 390-396
44. Stahr, P; Rupprecht, HJ; Voigtlander, T; Post, F; Otto, M; Erbel, R; Meyer, J
    A new thrombectomy catheter device (AngioJet) for the disruption of thrombi: An in vitro study
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    
    P. Stahr et al., "A new thrombectomy catheter device (AngioJet) for the disruption of thrombi: An in vitro study", CATHET C IN, 47(3), 1999, pp. 381-389
45. Pislaru, SV; Van de Werf, FJ
    The current role of thrombolytic therapy in the treatment of acute myocardial infarction
    FIBRINOLYSIS & PROTEOLYSIS
    
    S.V. Pislaru e F.J. Van de Werf, "The current role of thrombolytic therapy in the treatment of acute myocardial infarction", FIBRINOL PR, 13(2), 1999, pp. 78-90
46. Smith, BJ
    Thrombolysis in acute myocardial infarction: analysis of studies comparingaccelerated t-PA and streptokinase
    JOURNAL OF ACCIDENT & EMERGENCY MEDICINE
    
    B.J. Smith, "Thrombolysis in acute myocardial infarction: analysis of studies comparingaccelerated t-PA and streptokinase", J AC EMER M, 16(6), 1999, pp. 407-411
47. Vogt, A
    Antiplatelet drugs plus thrombolysis in myocardial infarction - Where are we now?
    BIODRUGS
    
    A. Vogt, "Antiplatelet drugs plus thrombolysis in myocardial infarction - Where are we now?", BIODRUGS, 11(6), 1999, pp. 377-383
48. Holper, EM; Giugliano, RP; Antman, EM
    Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction
    CORONARY ARTERY DISEASE
    
    E.M. Holper et al., "Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction", CORON ART D, 10(8), 1999, pp. 567-573
49. Michels, HR; Hoffman, JJML; Bar, FWHM
    Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: Comparison of infusion, single-bolus, and split-bolus administration
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    
    H.R. Michels et al., "Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: Comparison of infusion, single-bolus, and split-bolus administration", J THROMB TH, 8(3), 1999, pp. 213-221
50. Maksimenko, AV; Tischenko, EG
    New thrombolytic strategy: Bolus administration of tPA and urokinase-fibrinogen conjugate
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    
    A.V. Maksimenko e E.G. Tischenko, "New thrombolytic strategy: Bolus administration of tPA and urokinase-fibrinogen conjugate", J THROMB TH, 7(3), 1999, pp. 307-312
51. Cannon, CP
    Overcoming thrombolytic resistance - Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    
    C.P. Cannon, "Overcoming thrombolytic resistance - Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction", J AM COL C, 34(5), 1999, pp. 1395-1402
52. French, JK; Hyde, TA; Patel, H; Amos, DJ; McLaughlin, SC; Webber, BJ; White, HD
    Survival 12 years after randomization to streptokinase: The influence of thrombolysis in myocardial infarction flow at three to four weeks
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    
    J.K. French et al., "Survival 12 years after randomization to streptokinase: The influence of thrombolysis in myocardial infarction flow at three to four weeks", J AM COL C, 34(1), 1999, pp. 62-69
53. Weitz, JI; Stewart, RJ; Fredenburgh, JC
    Mechanism of action of plasminogen activators
    THROMBOSIS AND HAEMOSTASIS
    
    J.I. Weitz et al., "Mechanism of action of plasminogen activators", THROMB HAEM, 82(2), 1999, pp. 974-982
54. Ruef, J; Nordt, TK; Peter, K; Runge, MS; Kubler, W; Bode, C
    A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation
    THROMBOSIS AND HAEMOSTASIS
    
    J. Ruef et al., "A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation", THROMB HAEM, 82(1), 1999, pp. 109-114
55. Sakharov, DV; Barrett-Bergshoeff, M; Hekkenberg, RT; Rijken, DC
    Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: Comparison of nine plasminogenactivators in vitro
    THROMBOSIS AND HAEMOSTASIS
    
    D.V. Sakharov et al., "Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: Comparison of nine plasminogenactivators in vitro", THROMB HAEM, 81(4), 1999, pp. 605-612
56. Brophy, JM; Joseph, L; Theroux, P
    Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction
    MEDICAL DECISION MAKING
    
    J.M. Brophy et al., "Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction", MED DECIS M, 19(4), 1999, pp. 411-418
57. Van de Werf, FJ
    The ideal fibrinolytic: can drug design improve clinical results?
    EUROPEAN HEART JOURNAL
    
    F.J. Van de Werf, "The ideal fibrinolytic: can drug design improve clinical results?", EUR HEART J, 20(20), 1999, pp. 1452-1458
58. Hasdai, D; Holmes, DR; Topol, EJ; Berger, PB; Criger, DA; Hochman, JS; Bates, ER; Vahanian, A; Armstrong, PW; Wilcox, R; Ohman, EM; Califf, RM
    Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase - Results fromGUSTO-III
    EUROPEAN HEART JOURNAL
    
    D. Hasdai et al., "Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase - Results fromGUSTO-III", EUR HEART J, 20(2), 1999, pp. 128-135
59. Ross, AM
    New plasminogen activators: A clinical review
    CLINICAL CARDIOLOGY
    
    A.M. Ross, "New plasminogen activators: A clinical review", CLIN CARD, 22(3), 1999, pp. 165-171
60. Westermark, S; Wiksell, H; Elmqvist, H; Hultenby, K; Berglund, H
    Effect of externally applied focused acoustic energy on clot disruption invitro
    CLINICAL SCIENCE
    
    S. Westermark et al., "Effect of externally applied focused acoustic energy on clot disruption invitro", CLIN SCI, 97(1), 1999, pp. 67-71
61. Maksimenko, AV
    Third-generation plasminogen activators: A new direction in research
    BIOORGANICHESKAYA KHIMIYA
    
    A.V. Maksimenko, "Third-generation plasminogen activators: A new direction in research", BIOORG KHIM, 25(8), 1999, pp. 563-571
62. Patel, SC; Mody, A
    Cerebral hemorrhagic complications of thrombolytic therapy
    PROGRESS IN CARDIOVASCULAR DISEASES
    
    S.C. Patel e A. Mody, "Cerebral hemorrhagic complications of thrombolytic therapy", PROG CARD, 42(3), 1999, pp. 217-233
63. Zhang, YL; Hervio, L; Strandberg, L; Madison, EL
    Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    Y.L. Zhang et al., "Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases", J BIOL CHEM, 274(11), 1999, pp. 7153-7156
64. Antman, EM; Giugliano, RP; Gibson, CM; McCabe, CH; Coussement, P; Kleiman, NS; Vahanian, A; Adgey, AAJ; Menown, I; Rupprecht, HJ; Van der Wieken, R; Ducas, J; Scherer, J; Anderson, K; Van de Werf, F; Braunwald, E
    Abciximab facilitates the rate and extent of thrombolysis - Results of thethrombolysis in myocardial infarction (TIMI) 14 trial
    CIRCULATION
    
    E.M. Antman et al., "Abciximab facilitates the rate and extent of thrombolysis - Results of thethrombolysis in myocardial infarction (TIMI) 14 trial", CIRCULATION, 99(21), 1999, pp. 2720-2732
65. Moser, M; Nordt, T; Peter, K; Ruef, J; Kohler, B; Schmittner, M; Smalling, R; Kubler, W; Bode, C
    Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase
    CIRCULATION
    
    M. Moser et al., "Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase", CIRCULATION, 100(18), 1999, pp. 1858-1864
66. Helft, G; Elalamy, I; Beygui, F; Dambrin, G; Lecompte, T; Le Pailleur, C; Le Feuvre, C; Metzger, JP; Vacheron, A; Samama, MM
    New thrombolytic agents in myocardial infarction.
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
    
    G. Helft et al., "New thrombolytic agents in myocardial infarction.", ARCH MAL C, 92(4), 1999, pp. 411-417
67. Roberts, WC; Sobel, BE
    Burton Elias Sobel, MD: A conversation with the editor
    AMERICAN JOURNAL OF CARDIOLOGY
    
    W.C. Roberts e B.E. Sobel, "Burton Elias Sobel, MD: A conversation with the editor", AM J CARD, 83(3), 1999, pp. 418-436
68. Van de Werf, F
    What do new lytics add to t-PA?
    AMERICAN HEART JOURNAL
    
    F. Van de Werf, "What do new lytics add to t-PA?", AM HEART J, 138(2), 1999, pp. S115-S120
69. Califf, RM
    Glycoprotein IIb IIIa blockade and thrombolytics: Early lessons from the SPEED and GUSTO IV trials
    AMERICAN HEART JOURNAL
    
    R.M. Califf, "Glycoprotein IIb IIIa blockade and thrombolytics: Early lessons from the SPEED and GUSTO IV trials", AM HEART J, 138(1), 1999, pp. S12-S15
70. MCMECHAN SR; ADGEY AAJ
    OPTIMAL THROMBOLYTIC STRATEGIES FOR ACUTE MYOCARDIAL-INFARCTION - BOLUS ADMINISTRATION
    QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
    
    S.R. Mcmechan e A.A.J. Adgey, "OPTIMAL THROMBOLYTIC STRATEGIES FOR ACUTE MYOCARDIAL-INFARCTION - BOLUS ADMINISTRATION", QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 91(11), 1998, pp. 719-725
71. ROSS AM
    REPERFUSION THERAPY FOR MYOCARDIAL-INFARCTION - PRINCIPLES ESTABLISHED, APPLICATION STILL EVOLVING
    FIBRINOLYSIS & PROTEOLYSIS
    
    A.M. Ross, "REPERFUSION THERAPY FOR MYOCARDIAL-INFARCTION - PRINCIPLES ESTABLISHED, APPLICATION STILL EVOLVING", FIBRINOLYSIS & PROTEOLYSIS, 12, 1998, pp. 1-3
72. GULBA DC; BODE C; RUNGE MS; HUBER K
    THROMBOLYTIC AGENTS - AN UPDATED OVERVIEW
    FIBRINOLYSIS & PROTEOLYSIS
    
    D.C. Gulba et al., "THROMBOLYTIC AGENTS - AN UPDATED OVERVIEW", FIBRINOLYSIS & PROTEOLYSIS, 12, 1998, pp. 39-58
73. Meyer, J
    Clinical profile of saruplase: angiographic findings
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    
    J. Meyer, "Clinical profile of saruplase: angiographic findings", INT J CL PR, 1998, pp. 9-15
74. Betriu, A
    Clinical profile of saruplase: mortality and safety
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    
    A. Betriu, "Clinical profile of saruplase: mortality and safety", INT J CL PR, 1998, pp. 16-20
75. GUREVITZ O; GOLDFARB A; HOD H; FELDMAN M; SHENKMAN B; VARON D; ELDAR M; INBAL A
    RECOMBINANT VON-WILLEBRAND-FACTOR FRAGMENT AR545C INHIBITS PLATELET-AGGREGATION AND ENHANCES THROMBOLYSIS WITH RTPA IN A RABBIT THROMBOSIS MODEL
    Arteriosclerosis, thrombosis, and vascular biology
    
    O. Gurevitz et al., "RECOMBINANT VON-WILLEBRAND-FACTOR FRAGMENT AR545C INHIBITS PLATELET-AGGREGATION AND ENHANCES THROMBOLYSIS WITH RTPA IN A RABBIT THROMBOSIS MODEL", Arteriosclerosis, thrombosis, and vascular biology, 18(2), 1998, pp. 200-207
76. GERSHLICK AH; MORE RS
    RECENT ADVANCES - TREATMENT OF MYOCARDIAL-INFARCTION
    BMJ. British medical journal
    
    A.H. Gershlick e R.S. More, "RECENT ADVANCES - TREATMENT OF MYOCARDIAL-INFARCTION", BMJ. British medical journal, 316(7127), 1998, pp. 280-284
77. MICHELS HR
    THE IMPORTANCE OF SARUPLASE IN THE CONTEXT OF OTHER THROMBOLYTIC MEDICATIONS
    Reviews in contemporary pharmacotherapy
    
    H.R. Michels, "THE IMPORTANCE OF SARUPLASE IN THE CONTEXT OF OTHER THROMBOLYTIC MEDICATIONS", Reviews in contemporary pharmacotherapy, 9(6), 1998, pp. 403-409
78. ZEYMER U; MATEBLOWSKI M; NEUHAUS KL
    THROMBIN GENERATION IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION TREATED WITH FRONT-LOADED RT-PA AND RECOMBINANT HIRUDIN (HBW-023)
    Journal of thrombosis and thrombolysis
    
    U. Zeymer et al., "THROMBIN GENERATION IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION TREATED WITH FRONT-LOADED RT-PA AND RECOMBINANT HIRUDIN (HBW-023)", Journal of thrombosis and thrombolysis, 5(3), 1998, pp. 203-207
79. SALVIONI A; PEREGO GB; MARENZI G; GALLI S; ASSANELLI E; GUAZZI MD
    PLATELET ACTIVITY IN THE EARLY-STAGE OF ACUTE MYOCARDIAL-INFARCTION -RELATION TO TIME OF PRESENTATION, TREATMENT WITH EITHER TISSUE-PLASMINOGEN ACTIVATOR OR STREPTOKINASE AND CYCLOOXYGENASE INHIBITION
    Journal of thrombosis and thrombolysis
    
    A. Salvioni et al., "PLATELET ACTIVITY IN THE EARLY-STAGE OF ACUTE MYOCARDIAL-INFARCTION -RELATION TO TIME OF PRESENTATION, TREATMENT WITH EITHER TISSUE-PLASMINOGEN ACTIVATOR OR STREPTOKINASE AND CYCLOOXYGENASE INHIBITION", Journal of thrombosis and thrombolysis, 5(1), 1998, pp. 65-71
80. KANMATSUSE K; NAGAO K; KIKUSHIMA K; SHIOIRI K
    SYMPOSIUM ON MEDICAL DISEASES AND ANTITHROMBOTIC THERAPY - 1 - ANTITHROMBOLYTIC THERAPY FOR SCLEROTIC DISEASES - 3) ISCHEMIC-HEART-DISEASE (CORONARY THROMBOLYSIS)
    Internal medicine
    
    K. Kanmatsuse et al., "SYMPOSIUM ON MEDICAL DISEASES AND ANTITHROMBOTIC THERAPY - 1 - ANTITHROMBOLYTIC THERAPY FOR SCLEROTIC DISEASES - 3) ISCHEMIC-HEART-DISEASE (CORONARY THROMBOLYSIS)", Internal medicine, 37(2), 1998, pp. 203-205
81. FRENCH JK; HYDE TA; WHITE HD
    LEFT-VENTRICULAR FUNCTION FOLLOWING THROMBOLYTIC THERAPY FOR MYOCARDIAL-INFARCTION
    Journal of interventional cardiology
    
    J.K. French et al., "LEFT-VENTRICULAR FUNCTION FOLLOWING THROMBOLYTIC THERAPY FOR MYOCARDIAL-INFARCTION", Journal of interventional cardiology, 11(1), 1998, pp. 9-18
82. GURBEL PA; SEREBRUANY VL; SHUSTOV AR; BAHR RD; CARPO C; OHMAN EA; TOPOL EJ
    EFFECTS OF RETEPLASE AND ALTEPLASE ON PLATELET-AGGREGATION AND MAJOR RECEPTOR EXPRESSION DURING THE FIRST 24 HOURS OF ACUTE MYOCARDIAL-INFARCTION TREATMENT
    Journal of the American College of Cardiology
    
    P.A. Gurbel et al., "EFFECTS OF RETEPLASE AND ALTEPLASE ON PLATELET-AGGREGATION AND MAJOR RECEPTOR EXPRESSION DURING THE FIRST 24 HOURS OF ACUTE MYOCARDIAL-INFARCTION TREATMENT", Journal of the American College of Cardiology, 31(7), 1998, pp. 1466-1473
83. WHITE HD
    THROMBOLYTIC THERAPY AND EQUIVALENCE TRIALS
    Journal of the American College of Cardiology
    
    H.D. White, "THROMBOLYTIC THERAPY AND EQUIVALENCE TRIALS", Journal of the American College of Cardiology, 31(3), 1998, pp. 494-496
84. HAYES OW
    EMERGENCY MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION - FOCUS ON PHARMACOLOGICAL THERAPY
    Emergency medicine clinics of North America
    
    O.W. Hayes, "EMERGENCY MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION - FOCUS ON PHARMACOLOGICAL THERAPY", Emergency medicine clinics of North America, 16(3), 1998, pp. 541
85. CURZEN N; HAQUE R; TIMMIS A
    APPLICATIONS OF THROMBOLYTIC THERAPY
    Intensive care medicine
    
    N. Curzen et al., "APPLICATIONS OF THROMBOLYTIC THERAPY", Intensive care medicine, 24(8), 1998, pp. 756-768
86. DESCHENES I; FINKLE CD; WINOCOUR PD
    EFFECTIVE USE OF BCH-2763, A NEW POTENT INJECTABLE DIRECT THROMBIN INHIBITOR, IN COMBINATION WITH TISSUE-PLASMINOGEN ACTIVATOR (TPA) IN A RAT ARTERIAL THROMBOLYSIS MODEL
    Thrombosis and haemostasis
    
    I. Deschenes et al., "EFFECTIVE USE OF BCH-2763, A NEW POTENT INJECTABLE DIRECT THROMBIN INHIBITOR, IN COMBINATION WITH TISSUE-PLASMINOGEN ACTIVATOR (TPA) IN A RAT ARTERIAL THROMBOLYSIS MODEL", Thrombosis and haemostasis, 80(1), 1998, pp. 186-191
87. KAWASAKI T; SATO K; HIRAYAMA F; KOSHIO H; TANIUCHI Y; MATSUMOTO Y
    EFFECT OF A SYNTHETIC FACTOR XA INHIBITOR, YM-60828, ON BLOOD-VESSEL PATENCY IN COMBINATION WITH A THROMBOLYTIC AGENT AND ON BLOOD-LOSS FROM THE OPERATION SITE IN A RAT MODEL OF ARTERIAL THROMBOSIS
    Thrombosis and haemostasis
    
    T. Kawasaki et al., "EFFECT OF A SYNTHETIC FACTOR XA INHIBITOR, YM-60828, ON BLOOD-VESSEL PATENCY IN COMBINATION WITH A THROMBOLYTIC AGENT AND ON BLOOD-LOSS FROM THE OPERATION SITE IN A RAT MODEL OF ARTERIAL THROMBOSIS", Thrombosis and haemostasis, 79(4), 1998, pp. 859-864
88. Nordt, TK; Moser, M; Kohler, B; Ruef, J; Peter, K; Kubler, W; Bode, C
    Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction
    THROMBOSIS AND HAEMOSTASIS
    
    T.K. Nordt et al., "Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction", THROMB HAEM, 80(6), 1998, pp. 881-886
89. SITGES M; BOSCH X; BETRIU A
    OPTIMIZING THROMBOLYTIC TREATMENT IN ACUT E MYOCARDIAL-INFARCTION - ROLE OF NEW AGENTS AND THEIR ASSOCIATION WITH NEW ANTITHROMBOTIC THERAPIES
    Revista espanola de cardiologia
    
    M. Sitges et al., "OPTIMIZING THROMBOLYTIC TREATMENT IN ACUT E MYOCARDIAL-INFARCTION - ROLE OF NEW AGENTS AND THEIR ASSOCIATION WITH NEW ANTITHROMBOTIC THERAPIES", Revista espanola de cardiologia, 51(3), 1998, pp. 178-191
90. DEPERALTA GT; LAZARO RB
    REVASCULARIZATION SURGERY IN THE ACUTE-PHASE OF ACUTE MYOCARDIAL-INFARCTION
    Revista espanola de cardiologia
    
    G.T. Deperalta e R.B. Lazaro, "REVASCULARIZATION SURGERY IN THE ACUTE-PHASE OF ACUTE MYOCARDIAL-INFARCTION", Revista espanola de cardiologia, 51, 1998, pp. 44-50
91. MEISTER FL; STRINGER KA; SPINLER SA; GONZALEZ E; TALBERT RL; WEINER B; GUERRERO RM; SMITH R
    THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION
    Pharmacotherapy
    
    F.L. Meister et al., "THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION", Pharmacotherapy, 18(4), 1998, pp. 686-698
92. STRINGER KA
    TIMI GRADE FLOW, MORTALITY, AND THE GUSTO-III TRIAL
    Pharmacotherapy
    
    K.A. Stringer, "TIMI GRADE FLOW, MORTALITY, AND THE GUSTO-III TRIAL", Pharmacotherapy, 18(4), 1998, pp. 699-705
93. MODI NB; LIN YS; REYNOLDS T; SHAHEEN A; CHRISTIAN BJ
    PHARMACOKINETICS AND PHARMACODYNAMICS OF SIBRAFIBAN (RO-48-3657), AN ORALLY-ACTIVE IIB IIIA ANTAGONIST, ADMINISTERED ALONE OR IN COMBINATION WITH HEPARIN, ASPIRIN, AND RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN BEAGLES/
    Journal of cardiovascular pharmacology
    
    N.B. Modi et al., "PHARMACOKINETICS AND PHARMACODYNAMICS OF SIBRAFIBAN (RO-48-3657), AN ORALLY-ACTIVE IIB IIIA ANTAGONIST, ADMINISTERED ALONE OR IN COMBINATION WITH HEPARIN, ASPIRIN, AND RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN BEAGLES/", Journal of cardiovascular pharmacology, 32(3), 1998, pp. 397-405
94. MATSUNO H; KOZAWA O; NIWA M; ITO T; TANABE K; NISHIDA M; HAYASHI H; UEMATSU T
    EFFECT OF GR144053, A FIBRINOGEN-RECEPTOR ANTAGONIST, ON THROMBUS FORMATION AND VASCULAR PATENCY AFTER THROMBOLYSIS BY TPA IN THE INJURED CAROTID-ARTERY OF THE HAMSTER
    Journal of cardiovascular pharmacology
    
    H. Matsuno et al., "EFFECT OF GR144053, A FIBRINOGEN-RECEPTOR ANTAGONIST, ON THROMBUS FORMATION AND VASCULAR PATENCY AFTER THROMBOLYSIS BY TPA IN THE INJURED CAROTID-ARTERY OF THE HAMSTER", Journal of cardiovascular pharmacology, 32(2), 1998, pp. 191-197
95. COHEN JE; GINSBERG HJ; EMERY D; SCHWARTZ ML
    FATAL SPONTANEOUS SPINAL EPIDURAL HEMATOMA FOLLOWING THROMBOLYSIS FORMYOCARDIAL-INFARCTION
    Surgical neurology
    
    J.E. Cohen et al., "FATAL SPONTANEOUS SPINAL EPIDURAL HEMATOMA FOLLOWING THROMBOLYSIS FORMYOCARDIAL-INFARCTION", Surgical neurology, 49(5), 1998, pp. 520-522
96. GEBEL JM; SILA CA; SLOAN MA; GRANGER CB; MAHAFFEY KW; WEISENBERGER J; GREEN CL; WHITE HD; GORE JM; WEAVER WD; CALIFF RM; TOPOL EJ
    THROMBOLYSIS-RELATED INTRACRANIAL HEMORRHAGE - A RADIOGRAPHIC ANALYSIS OF 244 CASES FROM THE GUSTO-1 TRIAL WITH CLINICAL CORRELATION
    Stroke
    
    J.M. Gebel et al., "THROMBOLYSIS-RELATED INTRACRANIAL HEMORRHAGE - A RADIOGRAPHIC ANALYSIS OF 244 CASES FROM THE GUSTO-1 TRIAL WITH CLINICAL CORRELATION", Stroke, 29(3), 1998, pp. 563-569
97. LEDRICK D; KHALIL H; TITA J; MAHAJAN V
    SUDDEN APPEARANCE OF A MASS ON CHEST-X-RAY
    Postgraduate medical journal
    
    D. Ledrick et al., "SUDDEN APPEARANCE OF A MASS ON CHEST-X-RAY", Postgraduate medical journal, 74(870), 1998, pp. 245-246
98. DANGAS G; FIER C; AMBROSE JA
    THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION
    Medicamentos de actualidad
    
    G. Dangas et al., "THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION", Medicamentos de actualidad, 34(8), 1998, pp. 727-736
99. MURPHY NP; PRATICO D; FITZGERALD DJ
    FUNCTIONAL RELEVANCE OF THE EXPRESSION OF LIGAND-INDUCED BINDING-SITES IN THE RESPONSE TO PLATELET GP LLB LLLA ANTAGONISTS IN-VIVO/
    The Journal of pharmacology and experimental therapeutics
    
    N.P. Murphy et al., "FUNCTIONAL RELEVANCE OF THE EXPRESSION OF LIGAND-INDUCED BINDING-SITES IN THE RESPONSE TO PLATELET GP LLB LLLA ANTAGONISTS IN-VIVO/", The Journal of pharmacology and experimental therapeutics, 286(2), 1998, pp. 945-951
100. DENHEIJER P; VERMEER F; AMBROSIONI E; SADOWSKI Z; LOPEZSENDON JL; VONESSEN R; BEAUFILS P; THADANI U; ADGEY J; PIERARD L; BRINKER J; DAVIES RF; SMALLING RW; WALLENTIN L; CASPI A; PANGERL A; TRICKETT L; HAUCK C; HENRY D; CHEW P
     EVALUATION OF A WEIGHT-ADJUSTED SINGLE-BOLUS PLASMINOGEN-ACTIVATOR INPATIENTS WITH MYOCARDIAL-INFARCTION - A DOUBLE-BLIND, RANDOMIZED ANGIOGRAPHIC TRIAL OF LANOTEPLASE VERSUS ALTEPLASE
     Circulation
     
     P. Denheijer et al., "EVALUATION OF A WEIGHT-ADJUSTED SINGLE-BOLUS PLASMINOGEN-ACTIVATOR INPATIENTS WITH MYOCARDIAL-INFARCTION - A DOUBLE-BLIND, RANDOMIZED ANGIOGRAPHIC TRIAL OF LANOTEPLASE VERSUS ALTEPLASE", Circulation, 98(20), 1998, pp. 2117-2125